title: Post-transplant diabetes mellitus in children following renal transplantation.
abstract: PTDM plays a role in chronic allograft nephropathy and decreases graft and patient survival. Considering the serious outcome of chronic hyperglycemia, the importance of early recognition and the few data in children, in this retrospective analysis we studied the characteristics and risk factors of PTDM in 45 pediatric renal transplant recipients receiving Tac or CyA-based immunosuppression. Fasting blood sampling and OGTT were performed. PTDM has been developed in six patients (13%), while seven children (16%) had IGT, with the overall incidence of a glucose metabolic disorder of 29% in pediatric renal transplants. Patients in the PTDM + IGT group were younger and had higher systolic blood pressure and serum triglyceride level than children with normal glucose tolerance. Multivariate analysis identified Tac treatment, Tac trough level, steroid pulse therapy and family history of diabetes to be associated with the onset of PTDM. In pediatric renal transplants, OGTT and frequent assessment of blood glucose levels might be essential not only in the post-transplant management, but also prior to transplantation, particularly with family history of diabetes. Careful monitoring and modified protocols help to minimize the side effects of Tac and corticosteroids.
authors: First Department of Pediatrics, Semmelweis University, Budapest, Hungary.
authors: A
authors: A
authors: Prokai
authors: A
authors: A
authors: Fekete
authors: E
authors: E
authors: Kis
authors: G S
authors: GS
authors: Reusz
authors: P
authors: P
authors: Sallay
authors: A
authors: A
authors: Korner
authors: L
authors: L
authors: Wagner
authors: T
authors: T
authors: Tulassay
authors: A J
authors: AJ
authors: Szabo
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002648:Child; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000628:therapy; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D013256:Steroids / Q000494:pharmacology; D016559:Tacrolimus / Q000009:adverse effects
chemical_list: D001786:Blood Glucose; D007166:Immunosuppressive Agents; D013256:Steroids; D016559:Tacrolimus; D008775:Methylprednisolone